NASDAQ:HOOK

Hookipa Pharma Competitors

$12.68
+0.21 (+1.68 %)
(As of 04/14/2021 01:00 PM ET)
Add
Compare
Today's Range
$12.40
Now: $12.68
$12.73
50-Day Range
$11.48
MA: $12.89
$14.70
52-Week Range
$7.07
Now: $12.68
$15.52
Volume1,106 shs
Average Volume178,073 shs
Market Capitalization$329.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Competitors

Hookipa Pharma (NASDAQ:HOOK) Vs. ZYME, KRON, PHAT, STOK, OCUL, and RPTX

Should you be buying HOOK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Hookipa Pharma, including Zymeworks (ZYME), Kronos Bio (KRON), Phathom Pharmaceuticals (PHAT), Stoke Therapeutics (STOK), Ocular Therapeutix (OCUL), and Repare Therapeutics (RPTX).

Hookipa Pharma (NASDAQ:HOOK) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Hookipa Pharma and Zymeworks, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hookipa Pharma00703.00
Zymeworks03712.82

Hookipa Pharma currently has a consensus price target of $21.1429, suggesting a potential upside of 66.61%. Zymeworks has a consensus price target of $51.50, suggesting a potential upside of 67.59%. Given Zymeworks' higher possible upside, analysts plainly believe Zymeworks is more favorable than Hookipa Pharma.

Insider & Institutional Ownership

33.4% of Hookipa Pharma shares are owned by institutional investors. Comparatively, 75.1% of Zymeworks shares are owned by institutional investors. 4.0% of Hookipa Pharma shares are owned by insiders. Comparatively, 4.2% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Hookipa Pharma and Zymeworks' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hookipa Pharma-232.00%-39.58%-31.33%
Zymeworks-569.13%-44.06%-34.36%

Earnings & Valuation

This table compares Hookipa Pharma and Zymeworks' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hookipa Pharma$11.94 million27.58$-43,040,000.00($2.41)-5.26
Zymeworks$29.54 million47.68$-145,440,000.00($3.83)-7.97

Hookipa Pharma has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Hookipa Pharma has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Summary

Hookipa Pharma beats Zymeworks on 8 of the 14 factors compared between the two stocks.

Hookipa Pharma (NASDAQ:HOOK) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Hookipa Pharma and Kronos Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hookipa Pharma00703.00
Kronos Bio00403.00

Hookipa Pharma currently has a consensus price target of $21.1429, indicating a potential upside of 66.61%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 88.87%. Given Kronos Bio's higher probable upside, analysts plainly believe Kronos Bio is more favorable than Hookipa Pharma.

Earnings and Valuation

This table compares Hookipa Pharma and Kronos Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hookipa Pharma$11.94 million27.58$-43,040,000.00($2.41)-5.26
Kronos BioN/AN/AN/AN/AN/A

Kronos Bio has lower revenue, but higher earnings than Hookipa Pharma.

Profitability

This table compares Hookipa Pharma and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hookipa Pharma-232.00%-39.58%-31.33%
Kronos BioN/AN/AN/A

Institutional and Insider Ownership

33.4% of Hookipa Pharma shares are held by institutional investors. 4.0% of Hookipa Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hookipa Pharma (NASDAQ:HOOK) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Hookipa Pharma and Phathom Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hookipa Pharma00703.00
Phathom Pharmaceuticals10402.60

Hookipa Pharma currently has a consensus price target of $21.1429, indicating a potential upside of 66.61%. Phathom Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 34.35%. Given Hookipa Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Hookipa Pharma is more favorable than Phathom Pharmaceuticals.

Profitability

This table compares Hookipa Pharma and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hookipa Pharma-232.00%-39.58%-31.33%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Volatility & Risk

Hookipa Pharma has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Valuation and Earnings

This table compares Hookipa Pharma and Phathom Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hookipa Pharma$11.94 million27.58$-43,040,000.00($2.41)-5.26
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.82

Hookipa Pharma has higher revenue and earnings than Phathom Pharmaceuticals. Hookipa Pharma is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

33.4% of Hookipa Pharma shares are owned by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 4.0% of Hookipa Pharma shares are owned by insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Hookipa Pharma beats Phathom Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Hookipa Pharma (NASDAQ:HOOK) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Profitability

This table compares Hookipa Pharma and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hookipa Pharma-232.00%-39.58%-31.33%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Recommendations

This is a summary of recent ratings and target prices for Hookipa Pharma and Stoke Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hookipa Pharma00703.00
Stoke Therapeutics02602.75

Hookipa Pharma currently has a consensus price target of $21.1429, indicating a potential upside of 66.61%. Stoke Therapeutics has a consensus price target of $64.3333, indicating a potential upside of 86.15%. Given Stoke Therapeutics' higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Hookipa Pharma.

Insider and Institutional Ownership

33.4% of Hookipa Pharma shares are owned by institutional investors. 4.0% of Hookipa Pharma shares are owned by company insiders. Comparatively, 54.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Hookipa Pharma and Stoke Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hookipa Pharma$11.94 million27.58$-43,040,000.00($2.41)-5.26
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-19.17

Stoke Therapeutics has lower revenue, but higher earnings than Hookipa Pharma. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Hookipa Pharma has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Summary

Stoke Therapeutics beats Hookipa Pharma on 7 of the 13 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 33.4% of Hookipa Pharma shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Comparatively, 4.0% of Hookipa Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Ocular Therapeutix and Hookipa Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Hookipa Pharma00703.00

Ocular Therapeutix currently has a consensus target price of $24.80, indicating a potential upside of 47.09%. Hookipa Pharma has a consensus target price of $21.1429, indicating a potential upside of 66.61%. Given Hookipa Pharma's higher possible upside, analysts plainly believe Hookipa Pharma is more favorable than Ocular Therapeutix.

Volatility and Risk

Ocular Therapeutix has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ocular Therapeutix and Hookipa Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million300.68$-86,370,000.00($2.01)-8.32
Hookipa Pharma$11.94 million27.58$-43,040,000.00($2.41)-5.26

Hookipa Pharma has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ocular Therapeutix and Hookipa Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
Hookipa Pharma-232.00%-39.58%-31.33%

Summary

Hookipa Pharma beats Ocular Therapeutix on 8 of the 14 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Profitability

This table compares Repare Therapeutics and Hookipa Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
Hookipa Pharma-232.00%-39.58%-31.33%

Valuation & Earnings

This table compares Repare Therapeutics and Hookipa Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
Hookipa Pharma$11.94 million27.58$-43,040,000.00($2.41)-5.26

Repare Therapeutics has higher earnings, but lower revenue than Hookipa Pharma.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Repare Therapeutics and Hookipa Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
Hookipa Pharma00703.00

Repare Therapeutics currently has a consensus price target of $39.40, suggesting a potential upside of 14.70%. Hookipa Pharma has a consensus price target of $21.1429, suggesting a potential upside of 66.61%. Given Hookipa Pharma's higher probable upside, analysts plainly believe Hookipa Pharma is more favorable than Repare Therapeutics.

Institutional and Insider Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 33.4% of Hookipa Pharma shares are owned by institutional investors. 4.0% of Hookipa Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Repare Therapeutics beats Hookipa Pharma on 5 of the 9 factors compared between the two stocks.


Hookipa Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zymeworks logo
ZYME
Zymeworks
1.8$30.51+8.5%$1.29 billion$29.54 million-8.09News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$23.11+1.0%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$39.39+1.1%$1.22 billionN/A-2.82Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.50+4.2%$1.21 billionN/A-19.17
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.72+5.0%$1.21 billion$4.23 million-9.34News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$34.50+6.0%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.69+0.5%$1.18 billion$261.02 million5.96
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.98+16.9%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.62+1.9%$1.17 billion$59.70 million-196.20
NKTX
Nkarta
1.8$36.98+3.9%$1.17 billionN/A0.00Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.48+5.0%$1.13 billion$35.22 million-7.65
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.33+2.9%$1.12 billion$230,000.00-12.25Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.23+6.2%$1.12 billion$42.12 million-12.76Unusual Options Activity
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.64+4.0%$1.11 billionN/A-8.97Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.14+3.6%$1.08 billion$111.81 million-7.62
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.55+0.9%$1.08 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.51+4.9%$1.07 billionN/A-6.97
Zogenix logo
ZGNX
Zogenix
1.7$19.83+3.7%$1.06 billion$3.65 million-2.09
MannKind logo
MNKD
MannKind
1.4$4.45+5.4%$1.05 billion$63.04 million-21.19Increase in Short Interest
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.32+6.1%$1.05 billionN/A-8.61Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.56+4.5%$1.04 billion$120,000.00-3.91Analyst Upgrade
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$41.09+4.0%$1.04 billion$20.79 million-14.17Analyst Upgrade
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.24+2.8%$1.04 billionN/A-6.99Increase in Short Interest
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.23+3.8%$1.02 billionN/A-8.70
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.75+2.6%$996.70 million$122.47 million-27.88Analyst Downgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.85+5.7%$993.66 million$1.52 million-11.62Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.40+0.5%$982.60 million$800.40 million23.02
Prothena logo
PRTA
Prothena
2.1$24.07+2.9%$934.94 million$810,000.00-9.40Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.71+4.7%$918.28 millionN/A-12.77Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$27.22+0.5%$914.76 millionN/A-25.20
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.57+1.6%$895.14 million$227.19 million46.03
Radius Health logo
RDUS
Radius Health
1.1$19.63+3.7%$886.30 million$173.32 million-8.05Gap Down
Annexon logo
ANNX
Annexon
1.9$23.65+2.5%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.60+6.7%$873.54 million$23.96 million-17.97Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.46+3.2%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.19+2.4%$863.20 million$31.13 million-7.55Analyst Report
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$36.05+4.5%$845.56 millionN/A-10.70
Epizyme logo
EPZM
Epizyme
1.8$8.36+2.0%$833.11 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.50+1.0%$822.01 million$322.36 million125.00
Humanigen logo
HGEN
Humanigen
1.7$15.46+1.6%$813.46 millionN/A0.00Analyst Report
Increase in Short Interest
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$24.00+4.5%$806.52 million$296.70 million48.98Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.57+4.4%$758.12 million$40.89 million-3.64Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.31+2.1%$750.64 million$322.07 million-5.06Decrease in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$27.44+4.5%$732.39 million$148.36 million-7.13News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.52+4.0%$727.39 million$150,000.00-5.03
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.93+2.7%$723.91 million$2.22 million-17.24
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.53+8.4%$723.63 millionN/A0.00Increase in Short Interest
Chimerix logo
CMRX
Chimerix
1.3$8.39+1.0%$711.99 million$12.52 million-14.72Analyst Report
Increase in Short Interest
Ardelyx logo
ARDX
Ardelyx
1.6$8.00+10.0%$710.50 million$5.28 million-7.92Unusual Options Activity
Veru logo
VERU
Veru
1.4$10.12+2.9%$706.90 million$42.59 million-36.14Analyst Report
News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.